Ischemic optic neuropathy and giant cell arteritis.
AI Summary
This abstract discusses urgent treatment for arteritic ischemic optic neuropathy (AION) and challenges in non-arteritic AION (NAION) due to poor blood flow measurement and treatment options, exploring new therapies for both.
Abstract
Acute loss of vision due to anterior ischemic optic neuropathy, both arteritic and nonarteritic, demands investigation and where indicated, treatment as an emergency. While advances continue in the understanding of the pathophysiology and investigation of arteritic anterior ischemic optic neuropathy, the nonarteritic form presents a major therapeutic problem, particularly in the absence of a satisfactory clinical technique for the measurement of optic nerve head blood flow. Because of steroid resistance and side effects of chronic steroid therapy in giant cell arteritis, alternative immunosuppressive agents are being explored. In nonarteritic ischemic optic neuropathy, etiologic factors such as activated protein C resistance raise the possibility of evaluation for prothrombotic states, while calcium channel blockers offer prospects for the relief of ischemic effects at the cellular level.
MeSH Terms
Shields Classification
Related Articles5
Molecular regulation of neuroinflammation in glaucoma: Current knowledge and the ongoing search for new treatment targets.
ReviewTear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives.
Cross-Sectional StudyPotential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration.
ReviewErythropoietin: a candidate neuroprotective agent in the treatment of glaucoma.
ReviewPhysiological approaches to neuroprotection. boosting of protective autoimmunity.
Basic ScienceIs this article assigned to the wrong chapter(s)? Let us know.